By Nqobile Dludla and Siyanda Mthethwa

JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly’s Mounjaro launched in the country eight months earlier.

South Africa, which has the continent’s fourth-highest number of adults with diabetes, according to the International Diabetes Federation, would represents a key growth opportunity for obesity treatments.

“One in two adults right now in South Africa is living with excess weight or obesity,” Sara Norcross, general manager of Novo Nordisk South Africa, said at the launch event.

“We know that over two-thirds of women and about one in three men are currently living with obesity.”

Norcross said that Wegovy

See Full Page